EA201990847A1 - Способы диагностики и лечения резистентного или чувствительного к абиратеронацетат-глюкокортикоидной терапии метастатического кастрационно-резистентного рака предстательной железы - Google Patents

Способы диагностики и лечения резистентного или чувствительного к абиратеронацетат-глюкокортикоидной терапии метастатического кастрационно-резистентного рака предстательной железы

Info

Publication number
EA201990847A1
EA201990847A1 EA201990847A EA201990847A EA201990847A1 EA 201990847 A1 EA201990847 A1 EA 201990847A1 EA 201990847 A EA201990847 A EA 201990847A EA 201990847 A EA201990847 A EA 201990847A EA 201990847 A1 EA201990847 A1 EA 201990847A1
Authority
EA
Eurasian Patent Office
Prior art keywords
resistant
methods
metastatic
cancer
prostant
Prior art date
Application number
EA201990847A
Other languages
English (en)
Inventor
Вэйминь Ли
Кадзусиро Кавагути
Рио Ояма
Джаймала Пател
Денис Смирнов
Дебора Риччи
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201990847A1 publication Critical patent/EA201990847A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/5755—Neuropeptide Y
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90206—Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91045—Acyltransferases (2.3)
    • G01N2333/91074—Aminoacyltransferases (general) (2.3.2)
    • G01N2333/9108—Aminoacyltransferases (general) (2.3.2) with definite EC number (2.3.2.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящем документе описаны новые биомаркеры для выявления резистентности и чувствительности к абиратеронацетат-глюкокортикоидной терапии у пациента, имеющего метастатический кастрационно-резистентный рак предстательной железы. Кроме того, предложены способы диагностики и лечения резистентного к абиратеронацетат-глюкокортикоидной терапии и чувствительного к абиратеронацетат-глюкокортикоидной терапии метастатического кастрационно-резистентного рака предстательной железы.
EA201990847A 2016-09-30 2017-09-29 Способы диагностики и лечения резистентного или чувствительного к абиратеронацетат-глюкокортикоидной терапии метастатического кастрационно-резистентного рака предстательной железы EA201990847A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662402196P 2016-09-30 2016-09-30
PCT/US2017/054286 WO2018064470A1 (en) 2016-09-30 2017-09-29 Methods of diagnosing and treating abiraterone acetate- glucocorticoid -resistant or -sensitive metastatic castration resistant prostate cancer

Publications (1)

Publication Number Publication Date
EA201990847A1 true EA201990847A1 (ru) 2019-08-30

Family

ID=60186369

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990847A EA201990847A1 (ru) 2016-09-30 2017-09-29 Способы диагностики и лечения резистентного или чувствительного к абиратеронацетат-глюкокортикоидной терапии метастатического кастрационно-резистентного рака предстательной железы

Country Status (15)

Country Link
US (1) US20180092930A1 (ru)
EP (1) EP3519591A1 (ru)
JP (1) JP7197470B2 (ru)
KR (1) KR20190056420A (ru)
CN (1) CN109790586A (ru)
AU (1) AU2017336917A1 (ru)
BR (1) BR112019006404A2 (ru)
CA (1) CA3038964A1 (ru)
EA (1) EA201990847A1 (ru)
IL (1) IL265675A (ru)
JO (1) JOP20190067A1 (ru)
MX (1) MX2019003731A (ru)
PH (1) PH12019500675A1 (ru)
SG (1) SG10201912521PA (ru)
WO (1) WO2018064470A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7496975B2 (ja) * 2019-12-27 2024-06-10 富士フイルム株式会社 転移性去勢抵抗性前立腺癌の診断を補助する方法
CN111500728A (zh) * 2020-05-13 2020-08-07 无锡市申瑞生物制品有限公司 检测人ar-v7及ar基因表达的引物探针组合物、试剂盒及检测方法
WO2022067185A1 (en) * 2020-09-27 2022-03-31 Veru Inc. Methods of treating prostate cancer with minimal side effects

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014008155A1 (en) * 2012-07-02 2014-01-09 The General Hospital Corporation Diagnosis and monitoring treatment of prostate cancer
WO2014016830A1 (en) * 2012-07-25 2014-01-30 Mapi Pharma Ltd. Process and intermediates for the preparation of abiraterone acetate
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
US20150246060A1 (en) * 2013-03-15 2015-09-03 Iceutica Inc. Abiraterone Acetate Formulation and Methods of Use
KR20160058774A (ko) * 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
CN105517566A (zh) * 2013-08-21 2016-04-20 库瑞瓦格股份公司 用于治疗前列腺癌的组合物和疫苗
WO2015057250A1 (en) * 2013-10-18 2015-04-23 Psma Development Company, Llc Combination therapies with psma ligand conjugates
US20150147339A1 (en) * 2013-11-15 2015-05-28 Psma Development Company, Llc Biomarkers for psma targeted therapy for prostate cancer
ES2919098T3 (es) * 2014-01-27 2022-07-21 Epic Sciences Inc Detección de la expresión del antígeno de membrana específico de la próstata (PSMA) en células tumorales circulantes (CTC)
WO2015175305A1 (en) * 2014-05-12 2015-11-19 Janssen Pharmaceutica Nv Biological markers for identifying patients for treatment with abiraterone acetate

Also Published As

Publication number Publication date
US20180092930A1 (en) 2018-04-05
WO2018064470A1 (en) 2018-04-05
JP2019530452A (ja) 2019-10-24
JOP20190067A1 (ar) 2019-03-28
CN109790586A (zh) 2019-05-21
AU2017336917A1 (en) 2019-04-11
SG10201912521PA (en) 2020-02-27
EP3519591A1 (en) 2019-08-07
JP7197470B2 (ja) 2022-12-27
CA3038964A1 (en) 2018-04-05
KR20190056420A (ko) 2019-05-24
PH12019500675A1 (en) 2019-12-02
MX2019003731A (es) 2019-07-01
IL265675A (en) 2019-05-30
BR112019006404A2 (pt) 2019-06-25

Similar Documents

Publication Publication Date Title
MX2022006075A (es) Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer.
MX2020004567A (es) Metodos diagnosticos y terapeuticos para el cancer.
CY1122642T1 (el) Αντι-β7-η1 και anti-ctla-4 αντισωματα για τη θεραπευτικη αγωγη μη μικροκυτταρικου πνευμονικου καρκινου
EA201500835A1 (ru) Терапевтическая и диагностическая мишень для рака, включающая dll3-связывающие реагенты
EP3839510A3 (en) Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
MX2023001945A (es) Composiciones y metodos para el cribado de tumores solidos.
BR112016007864A2 (pt) método para a prognose e tratamento de metástase de câncer
MY176706A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
BR112016018044A2 (pt) teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer
WO2015094995A3 (en) Gene signature biomarkers of tumor response to pd-1 antagonists
MX2016012697A (es) Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales.
MX2019005683A (es) Metodos para detectar mutaciones de adn mediante el uso de extraccion con puntas mitra.
WO2014028862A9 (en) Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
MX2016012285A (es) Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
EA201990847A1 (ru) Способы диагностики и лечения резистентного или чувствительного к абиратеронацетат-глюкокортикоидной терапии метастатического кастрационно-резистентного рака предстательной железы
NZ714049A (en) Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
EA201790211A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака
CY1125020T1 (el) Mrna δεικτες βασιζομενοι σε ολικο αιμα για την προβλεψη του καρκινου προστατη και μεθοδοι ανιχνευσης αυτων
CY1120063T1 (el) Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo
EA201400996A1 (ru) Комбинированная терапия для лечения рака яичника
BR112016013976A2 (pt) método para determinar se um indivíduo é afetado por um câncer, método para discriminar entre câncer colorretal e pancreático dentre indivíduos que resultam ser positivos para o método, método para determinar o estágio de um câncer colorretal em um indivíduo afetado e uso de um kit de rt-pcr quantitativo para performar o método
MX2021003214A (es) Metodos terapeuticos y de diagnostico para el cancer de vejiga.
BR112014018374A8 (pt) Método para predizer a resposta d eum paciente com câncer, kit, anticorpo, método para o tratamento do câncer e composição farmacêutica
WO2015181555A8 (en) Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent
EA201501095A1 (ru) Эффективное лечение нмрл и прогностический клинический маркер чувствительной к лечению опухоли